Evaluating BioNTech: Insights From 12 Financial Analysts
Evaluating BioNTech: Insights From 12 Financial Analysts
評估biontech:來自12位金融分析師的見解
In the preceding three months, 12 analysts have released ratings for BioNTech (NASDAQ:BNTX), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中，12位分析師發佈了BioNTech (NASDAQ:BNTX) 的評級，呈現出從看多到看空的廣泛觀點。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $110.92, along with a high estimate of $122.00 and a low estimate of $98.00. This current average has decreased by 0.61% from the previous average price target of $111.60.
分析師們提供了更深入的見解，建立了12個月的價格目標，顯示出平均目標爲110.92美元，估價最高爲122.00美元，最低爲98.00美元。這一當前平均值從之前的平均價格目標111.60美元下降了0.61%。
Breaking Down Analyst Ratings: A Detailed Examination
分析師評級分析：詳細分析
A clear picture of BioNTech's perception among financial experts...
通過對最近分析師行動...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。